中国P站

The field of organ transplantation is continuously evolving, with a significant focus on improving graft survival and patient outcomes through advanced monitoring techniques. Early detection of complications such as acute kidney injury (AKI) and allograft rejection is paramount to successful transplantation. Recent research has explored novel biomarkers that can provide non-invasive and sensitive indicators of these critical events. Urinary microRNAs have emerged as promising candidates for predicting AKI post-kidney transplantation, offering high sensitivity and specificity for early detection and aiding in improved patient management and graft survival [1].

Similarly, the monitoring of kidney allograft rejection has seen advancements with the investigation of donor-derived cell-free DNA (dd-cfDNA). Elevated levels of dd-cfDNA have been shown to precede conventional markers of rejection, providing an early warning system that allows for timely therapeutic intervention and potentially preventing irreversible damage [2].

Beyond kidney transplantation, the principles of biomarker discovery extend to other solid organ transplants. In heart transplant recipients, circulating microRNAs are being investigated as potential biomarkers for the early detection of antibody-mediated rejection (AMR). Identifying specific microRNA signatures can assist in differentiating AMR from other forms of graft dysfunction, thereby guiding treatment strategies more effectively [3].

The role of donor-specific antibodies (DSAs) remains a critical aspect of long-term graft survival in kidney transplantation. Comprehensive reviews emphasize the importance of longitudinal monitoring of DSAs and associated immune responses. This approach is crucial for personalizing immunosuppression regimens and mitigating the risk of chronic rejection, which can significantly impair long-term graft function [4].

In liver transplantation, non-invasive diagnostic methods for distinguishing between operational tolerance and active rejection are highly sought after. Gene expression profiling of peripheral blood mononuclear cells (PBMCs) has shown potential in identifying specific gene signatures associated with tolerance. This research paves the way for more accurate and less invasive monitoring of liver allograft status [5].

Acute rejection episodes in lung transplantation also present a diagnostic challenge. Studies have evaluated the role of chemokines, such as CXCL9 and CXCL10, as biomarkers. Elevated levels of these chemokines in bronchoalveolar lavage fluid have been correlated with the presence of acute rejection, suggesting their utility as a diagnostic tool [6].

For kidney transplant recipients, a comprehensive understanding of the immune status is vital for preventing complications. The development of multiplex assays for detecting a panel of inflammatory cytokines in serum offers a comprehensive snapshot of the immune landscape. This approach can aid in the early identification of subclinical inflammation and rejection episodes, enabling proactive management [7].

Chronic antibody-mediated rejection (cAMR) in kidney transplantation is particularly challenging to diagnose and monitor. Research into urinary exosomal proteins as potential biomarkers for cAMR is ongoing. Identifying specific protein profiles within exosomes could lead to non-invasive diagnostic methods for this difficult-to-manage form of rejection [8].

In the context of hematopoietic stem cell transplantation (HSCT), monitoring immune reconstitution and predicting outcomes are crucial for patient recovery. Circulating tumor DNA (ctDNA) is being explored as a biomarker that can reflect engraftment kinetics and donor chimerism, offering insights into the immune recovery process after allogeneic HSCT [9].

Finally, distinguishing active kidney allograft rejection from non-rejection states non-invasively is a significant clinical goal. Urinary cell-free DNA (cfDNA) methylation patterns have shown promise as biomarkers. Specific methylation profiles within urinary cfDNA can serve as non-invasive indicators of rejection, complementing existing diagnostic methods [10].

Description

The current landscape of transplant immunology and clinical management is heavily reliant on the identification and validation of sensitive and specific biomarkers. These biomarkers are crucial for the early detection of adverse events, enabling timely interventions that can significantly impact graft survival and patient prognosis. In kidney transplantation, for instance, acute kidney injury (AKI) is a common complication. Novel research has highlighted the potential of urinary microRNAs as early biomarkers for AKI, demonstrating high sensitivity and specificity in their ability to detect this condition non-invasively [1].

Complementing the search for AKI biomarkers, donor-derived cell-free DNA (dd-cfDNA) is being investigated as a tool for monitoring kidney allograft rejection. Studies indicate that elevated dd-cfDNA levels can serve as an early warning sign of impending rejection, often appearing before changes in serum creatinine, thus allowing for prompt therapeutic adjustments [2].

The utility of microRNAs extends beyond kidney transplants, with research exploring their role in other solid organ transplant scenarios. For heart transplant recipients, circulating microRNAs are being examined for their ability to predict antibody-mediated rejection (AMR). A specific microRNA signature could assist clinicians in differentiating AMR from other causes of graft dysfunction, leading to more tailored treatment approaches [3].

Donor-specific antibodies (DSAs) represent a critical factor influencing long-term graft survival in kidney transplantation. A thorough understanding of their impact, coupled with continuous monitoring, is emphasized in recent reviews. This longitudinal surveillance of DSAs and their associated immune responses is essential for personalizing immunosuppression strategies and preventing the development of chronic rejection [4].

For liver transplant recipients, the ability to distinguish operational tolerance from active rejection non-invasively is of significant clinical interest. Gene expression profiling of peripheral blood mononuclear cells (PBMCs) has shown promise in this area. The identification of specific gene signatures associated with tolerance offers a potential pathway for non-invasive monitoring of liver allograft health [5].

In the context of lung transplantation, acute rejection episodes require reliable diagnostic tools. The evaluation of chemokines like CXCL9 and CXCL10 has revealed their potential as biomarkers for acute rejection. Elevated levels of these chemokines in bronchoalveolar lavage fluid have been found to correlate with the presence of rejection, suggesting their utility in clinical diagnosis [6].

Maintaining an optimal immune status in kidney transplant recipients is crucial for preventing complications. The development of a novel multiplex assay for detecting inflammatory cytokines in serum provides a comprehensive overview of the patient's immune condition. This can facilitate the early detection of subclinical inflammation and rejection, enabling proactive management strategies [7].

Chronic antibody-mediated rejection (cAMR) poses a significant challenge in kidney transplantation due to difficulties in early diagnosis and monitoring. Research into urinary exosomal proteins is exploring their potential as biomarkers for cAMR. The identification of specific protein profiles in exosomes could lead to non-invasive diagnostic methods for this complex form of rejection [8].

In hematopoietic stem cell transplantation (HSCT), particularly allogeneic transplantation, monitoring immune reconstitution is vital for patient recovery. Circulating tumor DNA (ctDNA) is emerging as a potential biomarker that can reflect engraftment kinetics and donor chimerism, providing valuable information about the immune recovery process post-transplant [9].

Lastly, the non-invasive diagnosis of kidney allograft rejection remains a key objective. Urinary cell-free DNA (cfDNA) methylation patterns are being investigated as potential biomarkers for differentiating active rejection from non-rejection states. Distinct methylation profiles within urinary cfDNA offer a promising avenue for non-invasive assessment of allograft status [10].

Conclusion

This collection of research highlights advancements in transplant monitoring through the identification of novel biomarkers. Studies explore urinary microRNAs and donor-derived cell-free DNA for early detection of kidney allograft injury and rejection, respectively. Circulating microRNAs are investigated for heart transplant rejection, while gene expression profiling aids in liver transplant monitoring. Donor-specific antibodies remain crucial for kidney transplant survival. Chemokines like CXCL9 and CXCL10 show promise for lung transplant rejection, and multiplex cytokine assays offer a comprehensive immune status overview in kidney recipients. Urinary exosomal proteins and cfDNA methylation patterns are explored for diagnosing chronic rejection in kidney transplants, and ctDNA is assessed for immune reconstitution in stem cell transplantation. These biomarkers collectively aim to improve graft survival and patient outcomes through non-invasive and early detection methods.

References

1. Xavier dlG, Laura G, Marta R. (2023) .J Clin Exp Transplant 10:1-12.

   , ,

2. Joanna ZL, Anna KB, Anna NB. (2022) .J Clin Exp Transplant 9:187-195.

   , ,

3. Maria LPGAS, Ana RTM, Luís MLR. (2021) .J Clin Exp Transplant 8:55-64.

   , ,

4. Fumihiko S, Yasuhiro I, Naoto Y. (2023) .J Clin Exp Transplant 10:1-9.

   , ,

5. Hitoshi S, Yoshihiko U, Yoshiaki Y. (2020) .J Clin Exp Transplant 7:145-156.

   , ,

6. Junichi S, Kiyoyasu A, Hiroyuki K. (2022) .J Clin Exp Transplant 9:201-209.

   , ,

7. Anna RBH, Maria FRS, Johan HVDM. (2021) .J Clin Exp Transplant 8:78-87.

   , ,

8. Kenjiro T, Masanori K, Shuji T. (2023) .J Clin Exp Transplant 10:25-33.

   , ,

9. Toru K, Kazuhiro T, Manabu M. (2020) .J Clin Exp Transplant 7:99-108.

   , ,

10. Yuki N, Masayuki A, Takeshi K. (2022) .J Clin Exp Transplant 9:158-167.

    , ,